Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Conclusions: According to current evidence, lenvatinib and apatinib had superior clinical effects for patients without previously systematic treatments, and regorafenib seemed to be more suitable for patients with previously targeted agent therapies. However, our conclusions still need more statistical validations, and more high-quality trials are expected.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research

Related Links:

ki Fukuda Kagawa Michitaka Kumada Maeda Predictive biomarkers of the response of hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim of this study was to identify clinically significant biomarkers of response to Lenvatinib therapy, to target strategies against HCC. Levels of circulating angiogenic factors (CAFs) were analyzed in blood samples collected at baseline and after introducing lenvatinib, from 74 Child-Pugh class A HCC patients who received lenvatinib. As CAF biomarkers, serum vascular endothelial growth factor (VEGF), fibroblast growth factor 19 (FGF19), F...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This study verified that MafF acted as a tumorsuppressor in HCC and revealed the upstream regulation mechanism of MafF, which provided anew perspective for potential therapeutic targets of HCC. PMID: 31969212 [PubMed - as supplied by publisher]
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Hepatocellular carcinoma (HCC), the most common type of liver cancer, develops as a complication of chronic liver disease. While palliative care has been shown to reduce rates of healthcare utilization in other populations, little is known of the impact of inpatient palliative care consultation for people with HCC.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
Authors: Zhang J, Ke M, Ren Y, Bi J, Du Z, Zhang M, Wang Y, Zhang L, Wu Z, Lv Y, Wu R Abstract Background: Hepatectomy remains one of the most effective treatments for patients with hepatocellular carcinoma (HCC); however, it can lead to serious complications. Irisin, a key regulator of energy metabolism, is secreted into the circulation by shedding of the extracellular portion of the fibronectin type III domain-containing 5 (FNDC5). We have shown that irisin administration alleviates liver ischemia-reperfusion injury in mice. However, the role of preoperative irisin levels in HCC patients who underwent hepatectomy...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Authors: S E, Naser M, Tarek B, Tarek S, Mahmoud A, K T, Narmin E, A E, A AR Abstract Background . Hepatocellular carcinoma (HCC) is a common cause of cancer-related mortality. The aim of this study is to evaluate the serum Malondialdehyde (MDA) and C-Reactive Protein (CRP) as prognostic markers among patients with HCC and its correlation with the tumor size, Child-Pugh and MELD score.Methods: The study was carried out on 180 patients with HCC and 180 cirrhotic controls. The patients were classified according to the Child-Pugh classification into Child A (n=50), B (n=62) and C (n=68), according to the MELD score in...
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
ConclusionsThis retrospective study showed that TARE therapy resulted in minimal toxicity in patients with HBV-derived HCC. Patients with CP A or BCLC A disease had superior survival outcomes compared to patients with CP B and BCLC B/C disease. These findings suggest that TARE is a viable treatment option for certain patient groups with HCC tumors secondary to HBV infection.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
Authors: Yan P, Zhou B, Ma Y, Wang A, Hu X, Luo Y, Yuan Y, Wei Y, Pang P, Mao J Abstract Hepatocellular carcinoma (HCC) is the most commonly diagnosed liver cancer, accounting for ~90% of all primary malignancy of the liver. Although various medical treatments have been used as systemic therapies, patient survival time may be extended by only a few months. Moreover, the underlying mechanisms of HCC development and progression remain poorly understood. In the present study, the single-cell transcriptome of one in vivo HCC tumor sample, two in vitro HCC cell lines and normal peripheral blood mononuclear cells were an...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Meng X, Shi Y, Xiang X, Li C, Ge X, Pan K, Liang Y Abstract The expression of miR-101 in carcinoma and para-carcinoma tissues of patients with liver cancer was studied. The carcinoma and para-carcinoma tissues of 67 patients with liver cancer treated in Chinese PLA General Hospital were collected, and the expression of miR-101 in carcinoma and para-carcinoma tissues was detected via reverse transcription-polymerase chain reaction (RT-PCR). The liver cancer HepG2 cell line was transfected with miR-101 mimics. Moreover, the influence of miR-101 overexpression on the proliferation of liver cancer cells was de...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
This study examines the prognostic index (PI) of alternative splices (ASs) in patients with hepatocellular carcinoma. The clinical features and splicing events of patients with HCC were downloaded from The Cancer Genome Atlas. AbstractPrevious studies have demonstrated the role of abnormal alternative splicing (AS) in tumor progression. This study examines the prognostic index (PI) of alternative splices (ASs) in patients with hepatocellular carcinoma (HCC). The clinical features and splicing events of patients with HCC were downloaded from The Cancer Genome Atlas (TCGA). Differentially expressed AS (DEAS) were compared be...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Abstract BACKGROUND: Hepatocellular carcinoma is the most common liver neoplasm and the sixth most common cancer worldwide. Its incidence has increased dramatically since the mid-2000s. Although surgical resection and liver transplantation are the main curative treatments, only about 20% of people with early hepatocellular carcinoma may benefit from these interventions. Treatment options for unresectable hepatocellular carcinoma include ablative and transarterial interventions - selective yttrium-90 microsphere transarterial radioembolisation - in addition to the drug sorafenib. OBJECTIVES: To determine the b...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Hepatocellular Carcinoma | Liver Cancer | Statistics | Study